CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Drug combination studies using imatinib and an SMO antagonist (sonidegib) demonstrated inhibition of self-renewal capacity specifically in CD34+ cells from chronic-phase CML patients but not in normal CD34+ HSCs18,19.